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Abstract 
Objective: To determine, “Is clofibrate a safe and effective adjunctive treatment to phototherapy 
for neonatal jaundice?” 
Study Design: Review of three English language, randomized controlled trials (one of which 
was double-blind) published between 2005-2009. 
Data sources:  Randomized controlled clinical trials comparing a one-time oral dose of 
clofibrate (100 mg/kg) plus phototherapy compared to phototherapy alone were found using 
Cochrane and EBSCOhost. 
Outcomes Measured:  The outcomes in all three studies were duration of phototherapy 
(measured in hours) and the safety of clofibrate (measured by the report of side effects at follow-
up). 
Results:  All three trials demonstrated that the one-time dose of oral clofibrate (100 mg/kg) in 
addition to photherapy significantly decreases the duration of photherapy needed for the 
treatment of neonatal jaundice.  Follow-up arrangements were made for two days, one week and 
one month for the Mohammadzadeh, Sakha, and Badeli trials respectively.  Two studies had no 
reported side effects noted at follow-up, but the Sakha trial noted an episode of rebound 
increases in bilirubin levels in an infant in the control group. 
Conclusions:  Clofibrate is an effective adjunctive treatment when combined with phototherapy 
for treatment of neonatal jaundice.  However, longer follow-up studies are needed to determine 
the true safety of the drug and the incidence of any long-term sequelae. 
Key Words: clofibrate, Atromid-S, neonatal jaundice. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 Neonatal jaundice is a common problem among newborns.  In fact, up to 60% of full-
term and 80% of pre-term newborns worldwide are diagnosed with jaundice within the first 
seven days of life.
4
  The term „jaundice‟ is generally characterized by a visible “yellowing” of 
the skin.  Once jaundice is noted in an infant, the severity of the condition is then determined by 
a blood test (total serum bilirubin) to determine if treatment is necessary.  Bilirubin is an end-
product of red cell breakdown in the body (this is called „indirect‟ bilirubin).  In a normal infant, 
the „indirect‟ bilirubin in the blood is converted into „direct‟ bilirubin in the liver.  Direct 
bilirubin is then excreted in the stool via the gut.  However, when the „indirect‟ bilirubin is not 
efficiently converted into „direct‟ bilirubin it accumulates in the body leading to the “yellow” 
color characteristic of jaundice.  Although many cases of newborn jaundice do not cause 
permanent damage, severe cases that are not treated quickly can lead to a brain damage referred 
to as, “kernicterus” which can lead to life-long complications.5 
The cost to treat neonatal jaundice can vary greatly from one infant to another depending 
on the severity of the condition.  For those with mild jaundice, the practitioner may choose to 
check the infant a couple times per week in the office to ensure the issue is resolving.  In 
moderate to severe cases, it is likely that the newborn will need to be treated with phototherapy.  
For those newborns whose condition requires in-patient treatment, it is likely that an extensive 
hospital bill will accrue due to phototherapy machines, monitors, and tests essential for tracking 
the condition. 
The high incidence of neonatal jaundice explains how important this condition is to 
practitioners.  Physician assistants in family medicine, pediatrics, emergency medicine and 
internal medicine are likely to be exposed to cases of neonatal jaundice during their career.  In 
addition, it is critical that practitioners have an understanding of the available treatments for 
neonatal jaundice, as this disease can be time-critical if the condition is severe. 
 Currently, the mainstay of treatment of neonatal jaundice is phototherapy where the 
infant is put in an incubator and exposed to lights, which helps the body excrete the excess 
bilirubin into the stool.  This form of therapy is effective, however, improvement takes days and 
can lead to dangerous side effects such as retinal damage, hyperthermia (or increased body 
temperature), and diarrhea.
1
  Although precautions are taken to ensure that side effects are 
minimal (such as covering the infants eyes during treatment) there is still a possibility of danger.  
In severe cases of neonatal jaundice, an exchange transfusion (remove blood and related products 
from the body and replace them with products from a donor) may be indicated to help prevent 
kernicterus.
3
  Other possible interventions include medications such as Phenobarbital, D-
penicillamine, and oral charcoal, but these treatments are not widely used and are still being 
researched for efficacy.
1
  Clofibrate (brand name Atromid-S) is another drug treatment being 
researched, but it is not considered an alternative to phototherapy.  Instead, it is thought that by 
adding a single dose of oral clofibrate (100 mg/kg) to the phototherapy treatment the duration of 
phototherapy needed would be decreased (because clofibrate helps indirect bilirubin convert to 
direct bilirubin).
2 
Objective 
 The objective of this limited systematic review is to determine, “Is clofibrate a safe and 
effective adjunctive treatment to phototherapy for neonatal jaundice?”   
 
Method 
 A thorough search was conducted by the author using the Cochrane Database of 
Systematic Reviews and Clinical Trials as well as EBSCOhost.  All studies were published in 
English, located in peer-reviewed journals, and dated between 2005-2009.  The key words used 
to search for studies were “clofibrate,” “Atromid-S,” and “neonatal jaundice.” The three studies 
utilized for this limited systematic review included newborns born either at term (38-41 weeks) 
or late pre-term (34-37 weeks) diagnosed with neonatal jaundice and admitted to the hospital 
(specifically those with a serum bilirubin between 15-29.9 mg/dl). The studies all used the same 
intervention of a single dose of oral clofibrate 100 mg/kg as an adjunct to phototherapy.  These 
intervention groups were compared to control groups, which only received phototherapy.  The 
main outcomes measured were the effect on jaundice (measured by duration of phototherapy) 
and the safety of clofibrate (measured by reported side effects).  Both of the outcomes measured 
are patient oriented evidence that matters (POEM).  All of the studies were randomized 
controlled trials (one of which was double-blind). 
The inclusion criteria for the studies were as follows: born at term (38-41 weeks) or late 
pre-term (34-37 weeks), breastfed, serum bilirubin between 15-29.9 mg/dl, and body weight 
between 2500-4000g.  The exclusion criteria for the studies were as follows: congenital 
abnormalities, G6PD deficiency, infection, dehydration, and hemolytic disorders (such as ABO 
or Rh incompatibility).  Table 1 includes the demographics for the studies utilized.  Statistics 
reported include p-values with confidence intervals (CI), numbers needed to treat (NNT), relative 
risk reduction (RRR), absolute risk reduction (ARR). 
 
Results: Table of demographics of included studies (Table 1) 
Study Type 
# 
Pts 
Age 
(years) Inclusion Criteria Exclusion Criteria W/D Interventions 
Badeli, Iran 
RCT 90 
38-41 
weeks  
breastfed, serum 
bilirubin between 
15-29.9 mg/dl; 
body wt between 
2500-4000g 
dehydration; infection; ABO 
or Rh incompatibility; G6PD 
deficiency; conjugated 
bilirubin >15% of total serum 
bilirubin; congenital 
anomalies 0 
phototherapy 
VS. 
phototherapy + 
clofibrate (100 
mg/kg x1 dose) 
Mohammad-
zadeh, India 
RCT 60 
38-41 
weeks  
breastfed; serum 
bilirubin 17-29.9 
mg/dl; healthy 
congenital anomalies; 
hemolytic disease; infection; 
dehydration; G6PD 
deficiency; conjugated 
bilirubin >15% of total serum 
bilirubin 0 
phototherapy 
VS. 
phototherapy + 
clofibrate (100 
mg/kg x1 dose) 
Sakha, India 
Double -
blind 
RCT 68 
34-37 
weeks  
non-hemolytic 
jaundice; no need 
for exchange 
transfusion 
congenital anomalies; 
hemolytic disorders; G6PD 
deficiency; sepsis or 
significant accompanying 
illness 0 
phototherapy 
VS. 
phototherapy + 
clofibrate (100 
mg/kg x1 dose) 
 
Outcomes Measured 
 The primary outcomes measured in all three studies were duration of phototherapy 
(measured in hours) and the safety of clofibrate, both of which are POEMs.  The safety of 
clofibrate was measured by the side effects reported by parents at follow-up after the infant was 
discharged home. 
Results 
The results pertaining to the duration of phototherapy were presented in continuous data 
as hours of phototherapy endured by the patients.  The data was then presented in the articles as a 
mean number of hours of phototherapy needed with the standard deviations (SD) also included 
(Table 2). For ease of communication, this limited systematic review will refer to the study  
Results: Efficacy of Clofibrate + Phototherapy on Duration of Phototherapy (Table 2)   
 Phototherapy duration (hours)- mean +/- SD Range/CI (hours) P-value 
 Clofibrate Control Clofibrate Control  
Badelli, 2008 38.8 +/- 7.5 68.75 +/- 15.4 20-48 36-96 < 0.001 
Mohammadzadeh, 2005 30 +/- 12.89 54 +/- 18.83 12-48. 24-96 < 0.0001 
Sakha, 2009 64.32 +/- 12.48 87.84 +/- 29.76 CI= 60-81.6 CI= 79.2-108 < 0.001 
SD= standard deviation; CI- confidence interval     
 
groups as control (phototherapy only) or clofibrate (phototherapy + 100 mg/kg of clofibrate x1 
dose). For the Badelli, 2008 study the infants in the clofibrate group needed an average of 38.8 
hours (SD=7.5; range 20-48) of phototherapy while the control group required 68.75 hours 
(SD=15.4; range 36-96), which was a significant difference (p<0.001).  The Mohammadzadeh, 
2005 study also had a significant difference in phototherapy duration (p<0.0001); the clofibrate 
group requiring a mean of 30 hours (SD=12.89; range 12-48) and the control group 54 hours 
(SD=18.83; range 24-96).  The newborns in the Sakha, 2009 clofibrate group received an 
average of 64.32 hours (SD=12.48; CI=60-81.6), while the control received 87.84 (SD=29.76; 
CI=79.2-108); this finding is significant (p<0.001). 
 The results for the incidence of side effects are summarized in Table 3.  For both the 
Badelli, 2008 and the Mohammadzadeh, 2005 studies there were no adverse effects reported at 
follow-up for any of the participants regardless of the group they were in (control versus 
clofibrate).  However, the Sakha, 2009 trial had one incidence of rebound increases in bilirubin 
levels (called rebound hyperbilirubinemia); the patient was a member of the control group.  The 
RRR and ARR were calculated to be 1% and 0.03% respectively.  Number needed to treat 
(NNT) was deemed to be -33 with the one-time oral clofibrate dose of 100 mg/kg. 
Results: Safety of Clofibrate as measured by side effects (Table 3)    
Study 
% of pts in control 
group with side effects 
% of pts in study 
group with side effects RRR ARR NNT 
Badelli, 2008 0 0 0 0 0 
Mohammadzadeh, 2005 0 0 0 0 0 
Sakha, 2009 0.03% 0 -1% -0.03% -33* 
SE= side effects; RRR= relative risk reduction; ARR= absolute risk reduction; NNT= numbers needed to treat 
* Since the outcome measured here is the incidence of side effects, the negative NNT means that for every 33 
patients who received clofibrate there was 1 less incidence of reported side effects than those who received 
phototherapy alone. 
 
Discussion 
 All three of the studies contained in this limited systematic review demonstrated a 
significantly lower duration of phototherapy needed for infants who received the one-time dose 
of clofibrate in addition to phototherapy (clofibrate group) when compared to newborns who 
received phototherapy alone (control group).  In addition, the newborns in the control group 
required an average of at least twenty-three additional hours of treatment with phototherapy 
before meeting qualifications for discharge when compared to the clofibrate group.  These results 
show that the hospital stay for newborns requiring treatment for jaundice can be decreased by a 
minimum of one day by simply adding a one-time dose of clofibrate. 
 The studies also seem to indicate that clofibrate is a safe drug to use in infants.  Each 
study arranged a follow-up appointment to determine if parents noted any side effects.  The 
Mohammadzdeh, 2005 study had the quickest follow-up at 2 days, while the Sakha, 2009 and 
Badeli, 2008 studies followed up at one week and one month respectively.  Although there were 
no reports of side effects at follow-up, it is not enough to deem the use of clofibrate safe due to 
the history of the drug.  
Clofibrate was originally used to treat high cholesterol and was taken at a dose of 500 mg 
per day by adults.  However, after studies demonstrated an increased mortality rate during active 
use of the drug in the 1980‟s, its production was discontinued in the United States.  In spite of 
this, studies also indicated mortality rates decrease significantly after termination of use.
6
  
Therefore, it is possible that the use of clofibrate may be completely safe for use in the treatment 
of neonatal jaundice as it is only a one-time dose and not a continuing medication regimen.  
Nevertheless, the studies in this limited systematic review did not follow-up nearly long enough 
to rule out long-term sequelae, which makes this a huge limitation to these studies. 
 Another limitation is the fact that each study used a different technique of administering 
phototherapy.  The Sakha, 2009 trial utilized units containing eight blue fluorescent tubes 
situated at 20-cm above the infant.  The Mohammadzadeh, 2005 trial also situated the lights 20-
cm above the infant, but used six white lamps instead of the blue used in the Sakha, 2009 trial.  
Finally, the Badeli, 2008 trial used four white lights positioned 30-cm above the newborn.  
Although the results in each trial demonstrated a decreased phototherapy time with clofibrate, the 
results would be more convincing with the same phototherapy technique used among the studies.  
In addition, it is possible that the difference in lights may have had an effect on the outcome of 
the studies. 
Conclusion 
 Clofibrate is an effective adjunctive treatment when combined with phototherapy for 
treatment of neonatal jaundice.  However, longer follow-up on patients and further research on 
long-term effects of the drug on the infant is needed to get this drug approved by the FDA for 
use in the United States. 
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